<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03763487</url>
  </required_header>
  <id_info>
    <org_study_id>Indicators of celiac activity</org_study_id>
    <nct_id>NCT03763487</nct_id>
  </id_info>
  <brief_title>The Aim of This Project is to Verify Whether a Depletion of B Cell Memory Subpopulation (&quot;Marginal-zone-like&quot;) CD19 + IgD + CD27 + and CD19 + IgM + CD27 + is a Useful Indicator of Hyposplenism in Patients With Celiac Disease</brief_title>
  <official_title>Marginal Zone Similar to B Lymphocytes in Peripheral Blood in Patients With Celiac Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Hradec Kralove</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Hradec Kralove</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is expected to confirm the hypothesis that hyposplenism in patients with celiac
      disease is not conditioned by a selective memory deficiency of B lymphocytes.

      Other objectives of project are:

        -  determination of gliadin 33-mer in faecal and urine as indicators patient´s adherence to
           gluten-free diet

        -  determination of citrulline in plasma as an indicator of the overall functional capacity
           enterocytes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ultrasound examination is focused to spleen size (spleen volumetry). Methodology of
      laboratory examinations is based on venous blood sampling for the determination of memory
      B-like marginal zone by flow cytometry; gliadin 33-mer (ELISA) determination in faecal and
      urine sample; blood plasma extraction for citrulline (high performance liquid chromatography,
      HPLC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>50 patients and 30 healthy blood donor</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>concentration of B-lymphocytes as parameter to evaluate treatment effect</measure>
    <time_frame>one year</time_frame>
    <description>assessment method: blood sampling, units: the measurement results are in absolute numbers, method: flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration of B-lymphocytes as parameter to evaluate treatment effect</measure>
    <time_frame>one year</time_frame>
    <description>assessment method: blood sampling, units: the measurement results are in percentage numbers, method: flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration of citrullin in plasma as parameter to evaluate treatment effect</measure>
    <time_frame>one year</time_frame>
    <description>assessment method: blood sampling, units: μmol/l (micromol/l; Citrullin cut-off for intestinal failure is &lt;20μmol / L), method: mass spectrometry (LC-MS instrumentation with internal isotopically labeled standard)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration of ornithin in plasma as parameter to evaluate treatment effect</measure>
    <time_frame>one year</time_frame>
    <description>assessment method: blood sampling, units: μmol/l (micromol/l), method: mass spectrometry (LC-MS instrumentation with internal isotopically labeled standard)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound examination: scaled to spleen size (spleen volumetry) Methodology of laboratory tests: venous blood sampling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy blood donors</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention in this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>venous blood sampling</intervention_name>
    <description>Venous blood samples to determine memory B lymphocytes.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>spleen volumetry</intervention_name>
    <description>Ultrasound examination of spleen to scaled the size.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed celiac disease

          -  age over 18 years

        Exclusion Criteria:

          -  haematological diseases and cancer

          -  infectious and non-infectious inflammation of the small intestine

          -  congenital or acquired immunodeficiency

          -  autoimmune disease

          -  immunosuppressant treatment

          -  diabetes mellitus

          -  pregnancy and lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ladislav Douda, M.D.</last_name>
    <phone>495 83 4240</phone>
    <email>ladislav.douda@fnhk.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <state>The Czech Republic</state>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ladislav Douda, M.D.</last_name>
      <phone>495 83 4240</phone>
      <email>ladislav.douda@fnhk.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1419299/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/18270242</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415212/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/11113071</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 12, 2018</study_first_submitted>
  <study_first_submitted_qc>December 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2018</study_first_posted>
  <last_update_submitted>December 3, 2018</last_update_submitted>
  <last_update_submitted_qc>December 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Hradec Kralove</investigator_affiliation>
    <investigator_full_name>Proff. Jan Bures, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>celiac sprue, celiac, hyposplenism, IgM memory, B lymphocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

